Reviewing Evidence For Use In Cost Effectiveness Models

Published Jun 17, 2013
Sheffield, United Kingdom - Health technology assessments typically require the development of a cost-effectiveness model which necessitates the identification, selection and use of other types of information beyond clinical effectiveness evidence in order to populate the model parameters. The reviewing activity associated with model development should be transparent and reproducible but can result in a tension between being both timely and systematic. Little procedural guidance existed in this area, until now. Researchers from the School of Health and Related Research at the University of Sheffield have developed guidance, informed by focus groups, on what might constitute a systematic and transparent approach to reviewing information to populate model parameters. Seven key themes were identified in this research including: selection and prioritisation of data to inform parameter estimates; reviewing methods; minimising bias, hierarchies of evidence; study selection; assessment of evidence and synthesis and analysis. The participants in in the focus groups considered these to be important areas where guidance would be particularly useful. Recommendations from this research included the use of rapid reviewing methods and the need to consider the trade-off between relevance and quality. Transparency in the reporting of review methods was emphasized. In addition, attention should be given to the reporting of parameters deemed to be more important to the model or where the preferred decision regarding the choice of evidence is equivocal. “The issues raised in this research are important in the field of HTA. The principles of evidence-based medicine lie at the heart of HTA; therefore questions regarding the identification and selection of evidence have an influence on the structure and conclusions of the cost-effectiveness model and subsequent decision making.” said Eva Kaltenthaler, PhD, Reader in Health Technology Assessment, ScHARR, University of Sheffield. The full study, “Reviewing the Evidence to Inform the Population of Cost-Effectiveness Models within Health Technology Assessments,” is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×